- Previous Close
17.17 - Open
15.01 - Bid 16.15 x --
- Ask 16.11 x --
- Day's Range
14.71 - 16.30 - 52 Week Range
11.00 - 27.94 - Volume
997,586 - Avg. Volume
445,987 - Market Cap (intraday)
15.162B - Beta (5Y Monthly) 1.90
- PE Ratio (TTM)
37.51 - EPS (TTM)
0.43 - Earnings Date May 15, 2025 - May 19, 2025
- Forward Dividend & Yield --
- Ex-Dividend Date Sep 9, 2022
- 1y Target Est
--
Syncom Formulations (India) Limited manufactures, markets, and sells pharmaceutical formulation products in India. It operates through Manufacturing and Dealing in Pharmaceutical Drug & Formulations, Trading of Commodities, and Renting of Properties segments. The company offers antibiotics/antiinfectives, anthelmintics, antimalarial, cardiac, derma, gastro, gynae, opthal, ortho, and pediatrics formulations. It provides life care, evolve, and right nutrition products under the Cratus brand. In addition, the company engages in the trading of commodities and renting of properties. It also exports its products. The company offers its pharmaceutical formulations products in various dosage forms, such as tablets, capsules, ointments, injections, liquids orals, and effervescent. Syncom Formulations (India) Limited was incorporated in 1988 and is based in Indore, India.
www.syncomformulations.com998
Full Time Employees
March 31
Fiscal Year Ends
Sector
Recent News: SYNCOMF.BO
View MorePerformance Overview: SYNCOMF.BO
Trailing total returns as of 4/7/2025, which may include dividends or other distributions. Benchmark is S&P BSE SENSEX (^BSESN) .
YTD Return
1-Year Return
3-Year Return
5-Year Return
Compare To: SYNCOMF.BO
Select to analyze similar companies using key performance metrics; select up to 4 stocks.
Statistics: SYNCOMF.BO
View MoreValuation Measures
Market Cap
16.14B
Enterprise Value
15.36B
Trailing P/E
40.00
Forward P/E
--
PEG Ratio (5yr expected)
--
Price/Sales (ttm)
4.37
Price/Book (mrq)
5.15
Enterprise Value/Revenue
3.97
Enterprise Value/EBITDA
25.92
Financial Highlights
Profitability and Income Statement
Profit Margin
10.02%
Return on Assets (ttm)
--
Return on Equity (ttm)
--
Revenue (ttm)
3.91B
Net Income Avi to Common (ttm)
391.45M
Diluted EPS (ttm)
0.43
Balance Sheet and Cash Flow
Total Cash (mrq)
920.06M
Total Debt/Equity (mrq)
4.54%
Levered Free Cash Flow (ttm)
--